Key result
Implantable loop recorders for unexplained syncope are linked to living ~1.2 years longer.
Why the study?
The impact of implantable loop recorders on survival and clinical outcomes in patients with recurrent unexplained syncope was unclear.
Cohort
Mean Difference: 1.2
ILR use in unexplained syncope warrants caution pending outcome data; leaves open whether device-guided management improves survival or reduces hospitalizations in real-world cohorts.
Aim: This study compares the outcomes of patients who receive an implantable loop recorder (ILR) for unexplained syncope to a control group without the diagnostic device in German claims data. Methods and materials: Patients with ILR were matched to a control group based on prior syncope events, age, gender and Charlson Comorbidity index (CCI). Survival, syncope hospitalizations, treatment and costs were compared. Results/conclusion: Four hundred and twelve ILR patients were matched with controls, mean age was 68, mean CCI was 2.7, 42% females. ILR patients lived on average 1.2 years longer than patients in the control group. Twenty-five percent of ILR patients received a therapeutic device compared with 5% in the control group. ILRs might help to diagnose and treat patients with positive impact on survival.
No takes yet. Share an insight, caveat, or question.
Perings et al. (2021) conducted a cohort in Recurrent unexplained syncope. Implantable loop recorder (ILR) vs. Control group without the diagnostic device was evaluated on Survival (1.2 years longer). Implantable loop recorders for recurrent unexplained syncope were associated with living on average 1.2 years longer and higher rates of receiving a therapeutic device (25% vs 5% for controls).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: